Coronavirus Disease 2019 (COVID-19) has caused an outbreak in China and is spreading worldwide [1].
As a result, South Korea could swiftly approve its first real-time reverse transcription (RT) PCR kit for COVID-19 testing on February 4, 2020 [4], following the country’s first reported case of COVID-19 on January 20, 2020 [5].
This issue of Ann Lab Med presents the guidelines for the laboratory diagnosis of COVID-19, which is followed in clinical laboratories in South Korea [6].
As local communities continue to be at risk of the virus spread, on February 23 2020, South Korea raised its national infectious disease alert to the highest level and further mobilized its resources to prevent the spread of COVID-19 [7].
A vast number of real-time RT PCR testing is being carried out thanks to the timely implementation of EUA; however, the country’s diagnostic capacity requires further improvement such as addressing the need to shorten the 6-hr turnaround time for testing in situations such as the current COVID-19 crisis.
To reduce the spread of COVID-19, the World Health Organization (WHO) has opened its Emergency Use Listing procedure for new submissions; as of February 12, 2020, 220 IVDs have been listed that will be evaluated for analytical sensitivity.
The Xpert Xpress SARS-CoV-2 (Cepheid, Sunnyvale, CA) and BioFire COVID-19 Test (BioFire Diagnostics, Salt Lake City, UT), which can be tested within 45 minutes, received EUA from the United States FDA as of March 23, 2020 [9].